Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia

Author(s): Kim Y, Kim H, Cho H, Bae Y, Suh K, et al.

Abstract

Background/aim:Although transplantation of MSC derived from bone marrow or adipose tissues has been shown in proangiogenic action in hindlimb ischemia model of nude mice, little information is available regarding comparison of the angiogenic potency between human adipose stromal cells (hADSC) and bone marrow stromal cells (hBMSC). We compared their therapeutic potential by transplantation of equal numbers of hADSC or hBMSC in a nude mice model of hindlimb ischemia.

Methods and results:One day after creating hindlimb ischemia, mice were randomized to receive hADSC transplantation (hADSC group), hBMSC transplantation (hBMSC group), or vehicle transplantation (Control group). Two weeks after transplantation, the laser Doppler perfusion index was significantly higher in the hADSC group and hBMSC group than in the control group. Comparison between hADSC and hBMSC group showed better recovery of blood flow in hADSC group than in hBMSC group. Conditioned media from hADSC (hADSC-CM) showed better in vitro tube formation of hADSC than conditioned media from hBMSC (hBMSC-CM). hADSC showed higher expression of MMP3 and MMP9 than hBMSC. A MMP inhibitor, GM6001, and the transfection of MMP3 or MMP9 siRNA oligonucleotides inhibited in vitro tube formation of hADSC. Transplantation of MMP3 or MMP9 siRNA oligonucleotieds-transfected hADSC showed lower blood flow recovery and higher tissue injury than control oligonucelotide-transfected cells.

Conclusion:This study showed that hADSC can be an ideal source for therapeutic angiogenesis in ischemic disease in terms of efficacy, accessibility and available tissue amounts.

Similar Articles

Stem cell transplantation in multiple sclerosis: current status and future prospects

Author(s): Martino G, Franklin RJ, Baron Van Evercooren A, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group

Progress and prospects: stem cells and neurological diseases

Author(s): Gögel S, Gubernator M, Minger SL

Isolation of amniotic stem cell lines with potential for therapy

Author(s): De Coppi P1, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, et al.

Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

Author(s): Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, et al.

The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Author(s): Auletta JJ, Bartholomew AM, Maziarz RT, Deans RJ, Miller RH, et al.

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals

Author(s): Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al.

Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis

Author(s): Liang J, Zhang H, Hua B, Wang H, Wang J, et al.

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

Author(s): Riordan NH, Ichim TE, Min WP, Wang H, Solano F, et al.

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy

Author(s): Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al.

Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis

Author(s): Darlington PJ, Boivin MN, Renoux C, François M, Galipeau J, et al.